Checchi Capital Advisers’s Bright Minds Biosciences DRUG Stock Holding History

Checchi Capital Advisers’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,828	Closed	-$8.06K	–	551
2023 Q2	$8.06K	Hold	2,828	–	–	﹤0.01%	575
2023 Q1	$6.22K	Hold	2,828	–	–	﹤0.01%	564
2022 Q4	$10.5K	Hold	2,828	–	–	﹤0.01%	543
2022 Q3	$17K	Hold	2,828	–	–	﹤0.01%	548
2022 Q2	$14K	Hold	2,828	–	–	﹤0.01%	582
2022 Q1	$21K	Hold	2,828	–	–	﹤0.01%	550
2021 Q4	$45K	Buy	+2,828	New	+$62.9K	﹤0.01%	540

Other funds holding DRUG

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Checchi Capital Advisers's DRUG Position: Q3 2023 in Review

Checchi Capital Advisers sold out of Bright Minds Biosciences (DRUG) in Q3 2023, closing a stake of 2,828 shares — an estimated $8.06K sold.

Checchi Capital Advisers first reported a position in DRUG in Q4 2021 and held it in 7 quarters. The position peaked at $45K in Q4 2021. 6 funds tracked by Wall St. Rank hold DRUG as of Q3 2023.

Checchi Capital Advisers reported no remaining Bright Minds Biosciences position as of Q3 2023 after selling out during the quarter.
Checchi Capital Advisers sold 2,828 Bright Minds Biosciences shares in Q3 2023, an estimated $8.06K.
Checchi Capital Advisers first reported a position in Bright Minds Biosciences in Q4 2021 and held it in 7 quarters.
Checchi Capital Advisers's Bright Minds Biosciences position peaked at $45K in Q4 2021.
6 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2023.

Based on Checchi Capital Advisers's 13F filing for Q3 2023, filed 13 Nov 2023.